Sign in Subscribe

chemo

A collection of 58 issues

Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google

High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer The phase III SOLARIS trial found median PFS was 11.8 months with high-dose vitamin D3 (8,000 IU then 4,000 IU daily) versus 10.3 months with standard-dose

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

Study evaluates potential hearing damage from oxaliplatin in preclinical model

Skip to content The CRC Digest ♥ LIVING WITH CRC Study evaluates potential hearing damage from oxaliplatin in preclinical model Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does

Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is informational

COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC The COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology) This content

Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea

Skip to content The CRC Digest ♥ LIVING WITH CRC Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea A systematic review details how irinotecan's active metabolite SN38 affects the intestinal microenvironment—including flora disruption, immune dysregulation, and barrier impairment—and explores current therapeutic approaches to manage this

HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases

Skip to content The CRC Digest ▸ TREATMENT HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases An updated meta-analysis of 12 studies (including 2 randomized controlled trials) encompassing more than 2,700 patients found that hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic therapy

Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy Researchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer) This